Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection

摘要: CONVENTIONAL randomized clinical trials of new treatments usually rely on end points that directly show the effect treatment outcomes such as quality or length life. In chronic diseases, like cancer, cardiovascular disease, and human immunodeficiency virus (HIV) infection, standard may be either distant in time rare, thus require a trial long duration, large sample size, both to demonstrate value treatment. A surrogate marker for point would allow more rapid completion investigations therapies. The use markers evaluating effective therapies HIV infection has drawn considerable attention. See also pp 158 161. perfect study therapeutic agent must biologically plausible, measurable all patients with predictive disease progression (ie, worsening